Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study

Zhong, Lieqiang; Long, Yuhang; Wang, Songzi; Lian, Rong; Deng, Lei; Ye, Zhixin; Wang, Zilian; Liu, Bin

doi:10.1016/j.placenta.2020.02.004

Cited by 29 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors also observed asprosin expression in placenta from both groups. 27 Moreover, a study performed by Baykus et al observed similar results, although asprosin levels were increased not only in GDM, but also in preeclampsia, severe preeclampsia and macrosomic fetuses, other interesting and unsolved result obtained was in intrauterine growth retardation where the levels of asprosin were significantly decrease. 28 …”

Section: Asprosin In Pathologies—metabolic Syndrome Relatedmentioning

confidence: 71%

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Luís

Fernandes

Soares

et al. 2020

Porto Biomedical Journal

View full text Add to dashboard Cite

Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin. In order to perform a state-of-the-art, nonsystematic review of asprosin, a study of the available literature was carried out in the main database (Pubmed) and the results were studied and correlated to better understand the mechanism of action of this hormone. Asprosin is not only associated with the metabolic syndrome features like glucose and lipid metabolism, insulin resistance, obesity and inflammation but also in other pathologies metabolic syndrome related like diabetic retinopathy, polycystic ovary syndrome and anorexia nervosa. A limited number of pathways were already unveiled although much more research is needed to better understand the therapeutical potential of asprosin in the metabolic syndrome.

show abstract

Section: Asprosin In Pathologies—metabolic Syndrome Relatedmentioning

confidence: 71%

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Luís

Fernandes

Soares

et al. 2020

Porto Biomedical Journal

View full text Add to dashboard Cite

show abstract

“…Moreover, Deng et al [31] noticed that the level of asprosin independently correlates with the urinary albumin/creatinine ratio, which is considered an index helpful in the detection of early diabetic nephropathy, and in combination with adiponectin level-asprosin could be a marker of early NAFLD diagnosis [32]. Furthermore, Zhong et al [33] noted that the level of asprosin increases in pregnant women with gestational diabetes mellitus (GDM) and their newborns, which, as suggested, may be a marker of early GDM diagnosis in this group. Baykus et al [34] revealed that the level of asprosin is elevated not only in pregnant women with GDM but also in women with pre-eclampsia.…”

Section: Asprosin and Insulin Resistance Diabetes And Obesitymentioning

confidence: 99%

“…Moreover, in women with intrauterine growth restriction, a significantly lower level of asprosin was observed than in healthy pregnant women. Asprosin expression was also observed in the placenta, but no significant correlations were found [33]. Asprosin level is also elevated in obese children more significantly than in overweight children, with girls having higher levels than boys [35].…”

Section: Asprosin and Insulin Resistance Diabetes And Obesitymentioning

confidence: 99%

Asprosin—A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature

Mazur-Biały

2021

Nutrients

View full text Add to dashboard Cite

Asprosin is a recently discovered protein released during fasting conditions mainly by adipocytes from white adipose tissue. As a glucogenic peptide, it stimulates the release of glucose from hepatic cells by binding to the OLFR734 receptor and leading to the activation of the G protein-cAMP-PKA pathway. As it crosses the blood–brain barrier, it also acts as an orexigenic peptide that stimulates food intake through activation of AgRP neurons in the hypothalamus; thus, asprosin participates in maintaining the body’s energy homeostasis. Moreover, studies have shown that asprosin levels are pathologically elevated in obesity and related diseases. However, the administration of anti-asprosin antibodies can both normalize its concentration and reduce food intake in obese mice, which makes it an interesting factor to combat obesity and related diseases. Current research also draws attention to the relationship between asprosin and fertility, especially in men. Asprosin improves age- and obesity-related decrease in fertility potential by improving sperm motility. It should also be mentioned that plasma asprosin levels can be differentially modulated by physical activity; intense anaerobic exercise increases asprosin level, while aerobic exercise decreases it. However, further research is necessary to confirm the exact mechanisms of asprosin activity and its potential as a therapeutic target.

show abstract

“…Currently, only little data regarding asprosin levels in pregnant women or children are available. So far, two clinical studies addressed maternal and newborn asprosin levels [3,26] whereas three studies examined serum asprosin in overweight and obese children [16,21,23].…”

Section: Introductionmentioning

confidence: 99%

“…Finally, they concluded that the "insulin resistance-related factor asprosin is expressed in placenta and is elevated in pregnant women complicated with GDM both before and after diagnosis, making it a potential predictor of GDM. Further research on the regulation of asprosin in placenta may improve the understanding of placenta induced insulin resistance mechanism [26].…”

Section: Introductionmentioning

confidence: 99%

Asprosin in pregnancy and childhood

et al. 2020

View full text Add to dashboard Cite

Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study

Cited by 29 publications

References 18 publications

A state of the art review on the novel mediator asprosin in the metabolic syndrome

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Asprosin—A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature

Asprosin in pregnancy and childhood

Contact Info

Product

Resources

About